Treatment methods for patients with hemophilia now include prophylactic or immune tolerance regimens that require frequent regular infusions of clotting factor concentrate, often beginning at an early age. If such regimens are undertaken, central…
When a sexual or nonsexual household exposure to HIV has occurred, at present it is widely recommended that antiretroviral treatment begin promptly, preferably within a few hours of exposure. Therefore, MASAC recommends that if such an exposure…
Much has changed since the previous MASAC Recommendation #36. Although the changes are summarized briefly below, MASAC strongly recommends that providers refer to the source document referenced below, entitled "2001 USPHS/IDSA Guidelines for the…
Much has changed since the previous MASAC Recommendation #42. Although the changes are summarized briefly below, MASAC strongly recommends that providers refer to the source document referenced below, entitled "Public Health Service Task Force…
Much has changed since the previous MASAC Recommendation #43. Since the 1998 HIV exposure guidelines, changes have included newer FDA-approved antiretroviral agents, new information regarding resistance testing of the source of the exposure, and…
The CDC Advisory Committee on Immunization Practices (ACIP) has made specific recommendations regarding immunization for hepatitis A and B and whether to monitor response. Although these recommendations are summarized briefly below, MASAC strongly…
Revisions: 132
Standards and Criteria for the Care of Individuals with Bleeding Disorders
“Hemophilia Treatment Centers (HTCs) provide value to people with hemophilia and other congenital coagulation disorders, their families and caregivers,…
The National Hemophilia Foundation and its Medical and Scientific Advisory Council are committed to clinical and basic research endeavors aimed at improving the care of or providing the cure for bleeding and clotting disorders. This includes…
Administration of normal coagulation factor genes to individuals with hemophilia, von Willebrand disease, and other rarer coagulation factor deficiencies represents the best hope for preventing bleeding episodes and their associated morbidity and…
The Plasma Protein Therapeutics Association (PPTA) is a worldwide association of manufacturers of products from human plasma such as clotting factor concentrates.
In 1991, the PPTA initiated what is now known as the International Quality Plasma…